Article
Multidisciplinary Sciences
Yutaka Hashimoto, Marisa Shiina, Shigekatsu Maekawa, Taku Kato, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Soichiro Yamamura, Sharanjot Saini, Z. Laura Tabatabai, Rajvir Dahiya, Yuichiro Tanaka
Summary: COMT expression is reduced in prostate cancer, and re-expression suppresses migration and enhances apoptosis. miR-195 regulates COMT expression in prostate cancer.
Article
Oncology
Che Lin, Ding-Ru Chen, Shou-Jen Kuo, Chi-Yen Feng, Dar-Ren Chen, Wei-Chung Hsieh, Po-Hsiung Lin
Summary: The aim of this study was to analyze the effects of treatment on estrogen quinone-derived adducts in breast cancer patients. The results suggest that hormonal therapy can significantly reduce the burden of estrogen quinones.
Article
Biochemical Research Methods
Yiyi Pu, Chao Li, Haining Yuan, Xiaoju Wang
Summary: This study identified and validated a panel of prostate cancer specific DNA methylation biomarkers with diagnostic value using multi-cancer data from TCGA and GEO. The biomarkers were able to differentiate between non-aggressive and aggressive prostate cancer, as well as distinguish between PRAD and normal prostate tissues and other urinary samples.
BMC BIOINFORMATICS
(2021)
Article
Veterinary Sciences
Kristine Walters, Alessia Stornetta, Foster Jacobs, Peter W. Villalta, Maria Razzoli, Marianne Grant, Beshay Zordoky, Alessandro Bartolomucci, Antonella Borgatti, Silvia Balbo
Summary: This study introduced a novel mass spectrometry approach for identifying doxorubicin-DNA adducts, aiming to personalize chemotherapy protocols for veterinary cancer patients. It also demonstrated the detection capability of doxorubicin and its related molecules in vitro and in vivo, laying the foundation for future biomarker development in veterinary oncology.
BMC VETERINARY RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Ercole Cavalieri, Eleanor Rogan
Summary: This article reviews evidence suggesting that many prevalent types of cancer share a common initiation mechanism, with endogenous estrogens playing a central role. It explains the role of estrogen-DNA adducts in cancer initiation and highlights two potential cancer prevention compounds, resveratrol and N-acetylcysteine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Martina Catalano, Daniele Generali, Marta Gatti, Barbara Riboli, Leda Paganini, Gabriella Nesi, Giandomenico Roviello
Summary: Deleterious aberrations in DNA repair genes are actionable in approximately 25% of metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination repair (HRR) is frequently altered in prostate cancer, particularly BRCA2 gene. Poly ADP-ribose polymerase inhibitors have shown antitumor activity and improved overall survival in mCRPC patients with somatic and/or germline alterations of HHR. However, the clinical use of liquid biopsy in prostate cancer compared to blood and tissue testing is currently very limited.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Bobby C. Liaw, Che-Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh
Summary: This study evaluated the feasibility and usefulness of blood-based biomarkers to identify platinum-sensitive mCRPC. Although some biomarkers were assessed, none were significantly associated with response to satraplatin.
Article
Environmental Sciences
Yiju Zhang, Qiao Wang, Yaoran Li, Jun Cheng, Xinyu Chen, Yu Zhang
Summary: This study developed a rapid and sensitive method for analyzing two DNA adducts induced by acrylamide exposure, and found that catechins can effectively inhibit the formation of these adducts.
Article
Medicine, General & Internal
Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, Siavash Foroughi, Stephen Brown, Lisa-Jane K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad
Summary: Genomic alterations in DDR genes are common in mCRPC. BRCA genes, especially BRCA2, are key prognostic biomarkers in mCRPC.
Review
Oncology
Cecile Manceau, Gaelle Fromont, Jean-Baptiste Beauval, Eric Barret, Laurent Brureau, Gilles Crehange, Charles Dariane, Gaelle Fiard, Mathieu Gauthe, Romain Mathieu, Raphaele Renard-Penna, Guilhem Roubaud, Alain Ruffion, Paul Sargos, Morgan Roupret, Guillaume Ploussard
Summary: Biomarkers have the potential to improve classification and monitoring in active surveillance for prostate cancer, allowing for more personalized prognostic assessments. While no single biomarker should dictate treatment decisions, they can each contribute as a piece of the puzzle in important decision-making processes. Further research is needed to fully understand the role of biomarkers in monitoring patient outcomes during active surveillance.
Article
Oncology
Gang Chen, Guojin Jia, Fan Chao, Feng Xie, Yue Zhang, Chuansheng Hou, Yong Huang, Haoran Tang, Jianjun Yu, Jihong Zhang, Shidong Jia, Guoxiong Xu
Summary: This study evaluated circulating tumor DNA as biomarkers for prostate cancer and found that ctDNA in blood and urine can be used for PCa detection, and the combination of these markers may increase the sensitivity and specificity of detection.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Philipp Krausewitz, Niklas Kluemper, Ayk-Peter Richter, Thomas Buettner, Glen Kristiansen, Manuel Ritter, Joerg Ellinger
Summary: This study found that SEPT9 and SHOX2 were highly methylated in PCa tissue and could discriminate disease status, tumor stage, and grade. In ccfDNA, the methylation of these two biomarkers allowed discrimination of localized and metastatic disease and increased shortly after prostate biopsy only in PCa patients. Therefore, mSEPT9 and mSHOX2 are promising non-invasive measures for PCa evaluation.
Review
Cell Biology
Supriya Borah, Rajeev Mishra, Sananda Dey, Surabhi Suchanti, Neil A. Bhowmick, Biplab Giri, Subhash Haldar
Summary: Circulating DNAs are fragmented DNA in blood plasma, including cell-free mitochondrial and nuclear DNA, and are altered in various pathological conditions. Mitochondrial DNA is associated with inflammation and elevated in cancer patients. It induces pro-inflammatory conditions and activates growth factors. It also triggers a positive feedback loop and activates pro-proliferating signaling in the tumor microenvironment. This review discusses the potential prognostic biomarkers and therapeutic candidates in different cancers, particularly prostate cancer.
Article
Genetics & Heredity
Chenming Zhang, Sicheng Ma, Xiaohui Hao, Zulong Wang, Zixue Sun
Summary: This study revealed that TK1 is overexpressed in prostate cancer, correlated with tumor stage and prognosis. The expression and methylation status of TK1 are linked to immune infiltrates and immunomodulators in prostate cancer. The research highlights the potential of TK1 as a target for prostate cancer therapy.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Marinella Corbetta, Chiara Chiereghin, Ilaria De Simone, Giulia Solda, Monica Zuradelli, Michele Giunta, Giovanni Lughezzani, Nicolo Maria Buffi, Rodolfo Hurle, Alberto Saita, Paolo Casale, Rosanna Asselta, Massimo Lazzeri, Giorgio Guazzoni, Stefano Duga
Summary: The study demonstrates that prostate biopsy results in a significant increase in circulating cell-free DNA in plasma of primary prostate cancer patients, with a significant enrichment of ctDNA post-biopsy. The released ccfDNA after biopsy contains a larger proportion of nucleosome-associated DNA fragments.
FRONTIERS IN ONCOLOGY
(2021)